Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

AVTR Insider Trading

Avantor, Inc. | Laboratory Analytical Instruments

Comprehensive Trading Performance Summary

The investment history of corporate insiders at Avantor, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Laboratory Analytical Instruments sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2026-03-11 21:10 2026-03-10 MEHRA SANJEEV K Director BUY $8.01 125,000 $1,001,250 475,000 +35.7%
2026-02-24 04:53 2026-02-19 LUCIER GREGORY T Director BUY $9.16 50,000 $458,000 50,000 +100.0%
2026-02-13 01:24 2026-02-12 SUMME GREGORY L Director BUY $9.40 100,000 $940,000 400,000 +33.3%
2025-12-10 01:11 2025-12-05 MEHRA SANJEEV K Director BUY $11.09 350,000 $3,881,500 350,000 +100.0%
2025-11-18 01:45 2025-11-17 Ligner Emmanuel Director, Officer - President and CEO BUY $11.35 87,500 $993,125 283,424 +44.7%
2025-10-31 16:46 2025-10-30 SUMME GREGORY L Director BUY $11.25 100,000 $1,125,000 300,000 +50.0%
2025-08-22 23:15 2025-08-21 SUMME GREGORY L Director BUY $12.56 100,000 $1,256,000 200,000 +100.0%
2025-08-06 23:32 2025-08-05 Eck Steven W Officer - SVP & Chief Accounting Officer SELL $11.39 3,476 $39,592 55,068 -5.9%
2025-05-27 23:58 2025-05-23 SUMME GREGORY L Director BUY $12.50 30,000 $375,000 100,000 +42.9%
2025-05-23 00:37 2025-05-22 SUMME GREGORY L Director BUY $12.65 20,000 $253,000 70,000 +40.0%
2025-05-09 23:51 2025-05-07 SUMME GREGORY L Director BUY $12.00 25,000 $300,000 50,000 +100.0%
2025-04-30 00:58 2025-04-28 Kang Lan Director BUY $12.57 5,000 $62,850 35,215 +16.5%
2025-04-30 00:58 2025-04-28 Peacock Jonathan M Director BUY $12.81 8,091 $103,646 202,715 +4.2%
2025-04-30 00:58 2025-04-29 Massaro Joseph R Director BUY $12.30 8,100 $99,630 35,038 +30.1%
2025-04-30 00:58 2025-04-28 SUMME GREGORY L Director BUY $12.50 25,000 $312,500 25,000 +100.0%
2025-03-01 00:53 2025-02-26 Bramwell James Officer - EVP Sales, Customer Excellence SELL $17.44 4,532 $79,036 86,605 -5.0%
2025-03-01 00:51 2025-02-26 Eck Steven W Officer - SVP & Chief Accounting Officer SELL $17.44 5,940 $103,581 39,571 -13.1%
2024-09-06 23:54 2024-09-05 Eck Steven W Officer - SVP & Chief Accounting Officer SELL $25.06 3,525 $88,337 29,544 -10.7%
2024-08-01 23:47 2024-07-30 Couturier Christophe Officer - EVP, AMEA SELL $27.01 10,100 $272,800 73,930 -12.0%
2024-03-12 23:46 2024-03-08 Eck Steven W Officer - SVP & Chief Accounting Officer SELL $25.63 3,685 $94,447 34,406 -9.7%
2024-03-02 00:46 2024-02-29 Bramwell James Officer - EVP Sales, Customer Excellence SELL $24.52 4,910 $120,393 96,233 -4.9%
2024-03-02 00:42 2024-02-29 Couturier Christophe Officer - EVP, AMEA SELL $24.53 13,074 $320,705 83,889 -13.5%
2024-02-28 01:02 2024-02-27 Bramwell James Officer - EVP Sales, Customer Excellence SELL $24.49 6,203 $151,911 101,143 -5.8%
2023-09-08 00:01 2023-09-07 Eck Steven W Officer - SVP & Chief Accounting Officer SELL $20.64 7,577 $156,389 28,187 -21.2%
2023-08-28 23:10 2023-08-25 Vanderhaegen Frederic Officer - EVP, Americas and Europe SELL $21.47 25,000 $536,750 160,735 -13.5%
2023-04-14 00:03 2023-04-11 Couturier Christophe Officer - EVP, AMEA SELL $21.18 1,498 $31,728 98,650 -1.5%
2023-03-07 00:38 2023-03-03 Brophy Gerard Officer - EVP, Biopharma Production SELL $25.00 3,914 $97,850 108,715 -3.5%
2023-03-02 00:46 2023-02-27 Brophy Gerard Officer - EVP, Biopharma Production SELL $25.00 3,059 $76,475 112,629 -2.6%
2023-03-02 00:44 2023-02-28 Couturier Christophe Officer - EVP, AMEA SELL $24.32 2,324 $56,520 100,717 -2.3%
2023-02-28 04:08 2023-02-23 Couturier Christophe Officer - EVP, AMEA SELL $24.24 3,078 $74,611 94,370 -3.2%
2023-02-23 01:01 2023-02-22 Couturier Christophe Officer - EVP, AMEA SELL $24.12 19,160 $462,139 97,160 -16.5%
2023-02-03 04:25 2023-02-02 Brophy Gerard Officer - EVP, Biopharma Production SELL $25.06 11,339 $284,155 102,385 -10.0%
2022-11-18 00:42 2022-11-16 Stubblefield Michael Director, Officer - CEO BUY $20.95 15,000 $314,250 429,500 +3.6%
2022-11-18 00:42 2022-11-16 Szlosek Thomas A Officer - EVP & CFO BUY $20.71 12,500 $258,850 35,668 +54.0%
2022-05-23 23:46 2022-05-20 Brophy Gerard Officer - EVP, Biopharma Production SELL $31.27 19,603 $612,986 96,935 -16.8%
2022-05-23 23:45 2022-05-23 Vanderhaegen Frederic Officer - EVP, Americas & Europe SELL $31.61 39,000 $1,232,790 126,764 -23.5%
2022-03-03 01:07 2022-03-01 Brophy Gerard Officer - EVP, Biopharma Production SELL $34.47 2,027 $69,871 136,221 -1.5%
2022-02-26 05:32 2022-02-23 Brophy Gerard Officer - EVP, Biopharma Production SELL $33.79 3,059 $103,364 125,181 -2.4%
2022-01-06 00:59 2022-01-03 Brophy Gerard Officer - EVP, Biopharma Production OPT+S $40.42 70,969 $2,868,915 131,312 0.0%
2021-12-29 00:56 2021-12-27 Couturier Christophe Officer - EVP, AMEA OPT+S $41.63 10,184 $423,960 110,497 0.0%
2021-12-24 00:28 2021-12-21 Couturier Christophe Officer - EVP, AMEA OPT+S $41.22 66,434 $2,738,702 110,497 0.0%
2021-12-11 01:00 2021-12-08 Couturier Christophe Officer - EVP, AMEA OPT+S $40.14 13,687 $549,366 110,497 0.0%
2021-12-03 16:31 2021-12-01 GUPTA RAJIV Director SELL $39.30 100,000 $3,930,000 879,347 -10.2%
2021-11-16 01:33 2021-11-11 Vanderhaegen Frederic Officer - EVP, Europe OPT+S $38.32 140,804 $5,395,483 154,495 0.0%
2021-11-03 03:24 2021-11-01 GUPTA RAJIV Director SELL $40.31 100,000 $4,031,000 979,347 -9.3%
2021-10-05 00:28 2021-10-01 GUPTA RAJIV Director SELL $39.94 100,000 $3,994,000 1,079,347 -8.5%
2021-09-23 00:16 2021-09-20 Stubblefield Michael Director, Officer - President and CEO SELL $42.37 141,300 $5,986,881 1,261,981 -10.1%
2021-09-03 00:55 2021-09-01 GUPTA RAJIV Director SELL $39.45 100,000 $3,945,000 1,179,347 -7.8%
2021-08-27 23:18 2021-08-26 Eck Steven W Officer - SVP & Chief Accounting Officer SELL $40.08 17,383 $696,711 14,148 -55.1%
2021-08-24 00:26 2021-08-20 GUPTA RAJIV Director SELL $38.81 100,000 $3,881,000 1,279,347 -7.2%
SHOW ENTRIES

How to Interpret $AVTR Trades

Not every insider transaction in Avantor, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $AVTR shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for AVTR

Insider activity data for Avantor, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $AVTR, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.